Lee Presses Indian Case For Saxagliptin Compulsory License
This article was originally published in Scrip
Executive Summary
Hyderabad-based Lee Pharma, which has been pursuing a compulsory license (CL) for AstraZeneca's Onglyza (saxagliptin) in India, has completed a crucial hearing in the case before India's new Patents Controller.